Observational studyInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2026
Preoperative immunonutrition for patients who undergo primary cytoreductive surgery for ovarian cancer.
Observational study in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectiveThe role of preoperative immunonutrition interventions in patients with gynecologic malignancies has not been well studied.
methodsWe performed a prospective observational study to assess the feasibility of a preoperative immunonutrition supplementation plan in patients with advanced ovarian cancer who underwent primary cytoreductive surgery between August 2019 and November 2022. Patients were encouraged to consume the provided immunonutrition supplement at each meal for up to 7 days prior to surgery. Patients completed standardized daily intake surveys, as well as laboratory tests and weight measurements throughout the study.
resultsA total of 29 patients were enrolled, 17 of whom met the inclusion criteria. Participants demonstrated a median weight gain of 3.8 kg over the study period, with high compliance, consuming an average of 2.2 Ensure Surgery Immunonutrition Shakes per day. On the day of surgery, 16 of 17 patients (94%) found the supplement satisfying, and 12 (71%) reported feeling better prepared for surgery. The median postoperative hospital stay was 8 days (interquartile range; 6-9), and the median time from surgery to initiation of chemotherapy was 36 days (interquartile range; 35-40). Preoperative laboratory assessments showed significant increases in neutrophils (+4.27 cells/μL, p < .001), C-reactive protein (+23.03 mg/L, p < .001), interleukin-6 (+160.22 pg/mL, p < .001), and interleukin-10 (+4.62 pg/mL, p = .279).
conclusionsImplementing a preoperative immunonutrition supplementation program in patients with advanced ovarian cancer undergoing primary cytoreductive surgery is feasible, and future studies are warranted to determine whether such a program improves patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.